Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Imagopaque

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The safety and diagnostic efficacy of the new non-ionic, monomeric contrast medium iopentol (Imagopaque) were evaluated and… Expand
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1997
1997
Summary. The efficacy and safety of the non-ionic contrast medium iopentol, 250 mg I/ml (Imagopaque®, Nycomed Imaging AS, Oslo… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 5
Is this relevant?
1997
1997
Summary. The non-ionic contrast medium iopentol (Imagopaque®, Nycomed Imaging AS, Oslo, Norway) 350 mg I/ml was compared for… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
1997
1997
Summary. Iopentol (Imagopaque®, Nycomed Imaging AS, Oslo, Norway) 300 mg I/ml was compared with iopromide (Ultravist®, Schering… Expand
  • table 3
  • table 1
  • table 2
  • table 4
  • table 5
Is this relevant?
1997
1997
Summary.Objectives. This trial was designed to compare the incidence of delayed postprocedural pain after administration of… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
1997
1997
Abstract. The elimination of the non-ionic contrast medium iopentol (Imagopaque®, Nycomed Imaging AS, Oslo, Norway) from the… Expand
  • table 1
  • table 2
  • figure 1
Is this relevant?
1997
1997
Summary. A non-ionic, monomeric, low-osmolar contrast medium, iopentol (Imagopaque®, Nycomed Imaging AS, Oslo, Norway) has been… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
1997
1997
Abstract. The aim of the study was to evaluate and compare the hemodynamic and electrocardiographic effects following injection… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
1994
1994
In pediatric radiology there is a great demand for a safe contrast medium. In this pediatric CT trial, the safety, tolerability… Expand
  • table 1
  • figure I
  • figure 2
  • table 4
  • table 5
Is this relevant?